50 results
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
will not be considered Sublicensees. 1.205 “Target” means one or more biological targets identified by BioNTech in respect of which BioNTech wishes … AE Licensed Products. (b) Nomination of Targets. If BioNTech wishes to conduct the Evaluation or exercise its Activity Enhancement Option, in each case
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
for multiple myeloma, which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR which … will preserve a portion of the patient’s normal, healthy T cells to maintain immunity. It targets an antigen, TRBC1 found on approximately 40% of T cell
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
CARs for the multiple myeloma targets, BCMA and CD19. Initial data from the MCARTY Phase 1 study in multiple myeloma presented at ASH in December 2023 … in Neuroblastoma – Phase 1 MAGNETO Study AUTO6NG contains a CAR that targets GD2 alongside additional programming modules to enhance the activity
8-K
AUTL
Autolus Therapeutics plc
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
Option must be exercised with respect to a given biological target or combination of targets. There is a cap on the total option exercise fee
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
11 Dec 23
Regulation FD Disclosure
8:31am
Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies Session date and time: Saturday, December 9, 2023 … CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR which is designed for improved killing of target cell
10-Q
mlc4onx
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
bq6ifji2qq3qlvh7y
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
63xbizyj
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
9vwr0ly
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
rxopsb
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
i0ue qh30x
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.3
auifncz2
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.3
6pt2ufvjafb9i ek
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.1
j8l1v4d63nloct6vt
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.2
kixw9
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
g22o5o3z47vu5u pk3
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
sergjl g3q07
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-99.1
ra7lku fm8r
3 Nov 22
Index to Condensed Consolidated Financial Statements
10:31am
6-K
EX-99.3
jka380l9j9r3alq
3 Nov 22
Index to Condensed Consolidated Financial Statements
10:31am
6-K
EX-99.1
m0qubwca
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm